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Abstract
Background: Enhancing osteogenic capabilities of bone matrix for the treatment of fractures and segmental
defects using growth factors is an active area of research. Recently, synthetic peptides like AC- 100, TP508 or p-15
corresponding to biologically active sequences of matrix proteins have been proven to stimulate bone formation.
The platelet-derived growth factor (PDGF) BB has been identified as an important paracrine factor in early bone
healing. We hypothesized that the combined use of PDGF-BB with synthetic peptides could result in an increase in
proliferation and calcification of osteoblast-like cells.
Methods: Osteoblast-like cell cultures were treated with PDGF and synthetic peptides, singly and as combinations, and
compared to non-treated control cell cultures. The cultures were evaluated at days 2, 5, and 10 in terms of cell
proliferation, calcification and gene expression of alkaline phosphate, collagen I and osteocalcin.
Results: Experimental findings revealed that the addition of PDGF, p-15 and TP508 and combinations of PDGF/AC-100,
PDGF/p-15 and PDGF/TP508 resulted in an increase in proliferating osteoblasts, especially in the first 5 days of
cultivation. Proliferation did not significantly differ between single factors and factor combinations (p > 0.05). The onset
of calcification in osteoblasts occurred earlier and was more distinct compared to the corresponding control or PDGF
stimulation alone. Significant difference was found for the combined use of PDGF/p-15 and PDGF/AC-100 (p < 0.05).
Conclusions: Our findings indicate that PDGF exhibits cooperative effects with synthetic peptides in differentiation
and proliferation. These cooperative effects cause a significant early calcification of osteoblast-like cells (p < 0.05).
We suggest the combination of synthetic peptides and PDGF as a potential clinical approach for accelerating bone
healing or coating osteosynthesis materials.
Background
Enhancing the osteogenic capabilities of bone matrix for
the treatment of fractures and segmental bone defects is
an active area of research. It is well-known that the use of
oligopeptides or growth factors promotes osteogenic cell
proliferation and differentiation in vitro and in vivo [1-4].
There are many different pathways in research to address
the acceleration of fracture healing.
The platelet-derived growth factor (PDGF), a paracrine
factor in fracture hematoma, has proven its efficacy in
early bone healing [5,6]. It is a homodimeric or heterodi-
meric protein with A and B polypeptide chains that has
three possible isoforms: PDGF-AA, PDGF-BB and PDGF-
AB [7]. PDGF is a heat-stable, positively charged protein
produced by osteoblasts, platelets and monocytes/macro-
phages. PDGF-B has higher mitogenic and chemotactic
potential and also a higher affinity to bone matrix than
PDGF-A [8]. Although it is established that bone cells pro-
duce and respond to PDGF-B [9], the role of this factor in
the healing of fractures has not been fully defined. PDGF-
B staining was detected in macrophages and in some pri-
mitive mesenchymal cells around the hematoma on day 3
after the fracture. These findings support the hypothesis* Correspondence: thomas.vordemvenne@ukmuenster.de1Department of Trauma, Hand and Reconstructive Surgery, University
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that PDGF-B is released during platelet degranulation and
acts as a paracrine agent [5,10].
With respect to potential coating techniques, PDGF-
loaded poly(l-lactide) (PLLA) membranes are used to
enhance tissue regeneration [11]. Different release kinetics
of PDGF from different materials have been investigated
[12] and led to many potential uses of coating materials in
periodontal and trauma surgery for implant in-growths or
acceleration of bone healing [13,14].
AC-100 (Dentonin™) corresponding with the central
sequence of human MEPE (matrix extracellular phospho-
protein or OF45: osteoblast/osteocyt factor 45) is a stimu-
lator for new bone formation by increasing the number of
osteoblasts. Cleaved from the SIBLING (Small Integrin-
binding LIgand, N-linked Glycoprotein) family, MEPE is
secreted in the bone during proliferation and early
maturation phases by fully differentiated osteoblasts. It is
suggested that the osteogenic activity of AC-100 is
mediated by activating integrin signalling pathways in
osteoblasts [15]. Furthermore, MEPE has been also shown
to promote the formation of reparative dentin [15,16].
The thrombin-related peptide TP508 (Chrysalin™) is a
synthetic 23-amino acid peptide representing the natural
sequence of the receptor-binding domain of human throm-
bin (prothrombin amino acids 508-530). This peptide was
initially identified by its ability to compete with thrombin
for binding to a high-affinity thrombin receptor on fibro-
blasts and to generate receptor occupancy-dependent
mitogenic signals. Subsequently, a number of studies
demonstrated a potential therapeutic role of TP508 in tis-
sue repair [17,18]. In fracture repair, TP508 has been
shown to promote angiogenesis and enhance bone strength
formation by increased induction of early growth factors
and inflammatory mediators [19].
p-15 (Pepgen™) is an FDA-approved, tissue-engineered
product that contains anorganic bone mineral (ABM) scaf-
fold and is coated with an active peptide sequence. This
peptide surface is derived from the a1 chain of collagen
Type I and promotes the attachment and proliferation of
fibroblasts and osteoblasts to ABM [20,21].
The aim of this study was to test the hypothesis that the
combined use of PDGF-BB with synthetic peptides could
result in an increase in proliferation and calcification of
osteoblast-like cells. This was done by comparing the
effects of PDGF and the peptides AC-100, TP508 or p-15
singly or combined in osteoblast-like cells stimulation.
Methods
Isolation of human osteoblast-like cells
Bone specimens were obtained from femur neck of
patients (age 50-80 years) undergoing total hip replace-
ment according to the guidelines of the local Ethics Com-
mittee. Primary osteoblast cultures were obtained from
bone specimens using a previously described technique
[22] slightly modified for our experiments. Briefly, trabe-
cular bone fragments were cut into pieces, thoroughly
rinsed in phosphate buffered saline (PBS) and kept
in MEM:HAMS F12 (1:1) (Biowest, Berlin, Germany)
medium containing 10% FCS and antibiotics (100 U peni-
cillin/ml, 100 μg streptomycin/ml) (Gibco, Life Technol-
ogies). Cultures were initiated in 75-cm2 culture flasks
(BD Biosciences, Bedford, MA) within 3 h and incubated
at 37°C in a humidified atmosphere of 5% CO2. Culture
medium was replaced 3 × weekly. Under these condi-
tions, cells migrated out of the bone-forming a mono-
layer within 3-4 weeks. Primary cell layers were washed
in PBS, detached with trypsin EDTA solution (Biowest,
Berlin, Germany) and subcultured once in a 1 to 3 ratio.
After growth to confluence, cells were released from cul-
ture dish as described above. Cells were either frozen at
passage 1 or used for experiments in passage 3. Human
recombinant PDGF-BB was obtained from R&D Systems,
Inc., U.S.A, AC-100 from Acologix, Inc., U.S.A. P-15 and
TP508 were synthesized by Sigma-Aldrich, Germany.
Stimulation of osteoblast-like cells
Cells from ≥ 5 patients were pooled and seeded at a den-
sity of 1 × 104 in 24-well tissue culture plates (Falcon,
Becton Dickinson Labware, USA) and chamber slides
(Nalge Nunc International Corp., USA). Cells were cul-
tured as described above. In order to gain osteoinductivity,
the medium was supplemented with L-ascorbic acid-2-
phosphate (0.1 mM) and ß-glycerolphhosphate (10 mM).
Stimulation of cultures was done over a period of 2, 5 and
10 days, with the growth factors and peptides listed in
Table 1. Cultures without additional growth factors and
peptides served as controls.
Proliferation and cell number
Growth of cultures was determined cytologically by count-
ing proliferating cells using Ki-67 antibody (Dako Cytoma-
tion, Hamburg, Germany) and total cells (methyl green
stain). Briefly, after removal of the medium, cells were
rinsed twice in PBS, fixed with methanol on the chamber
slides and treated with blocking serum followed by incuba-
tion with Ki-67 antibody according to the manufacturer’s
specifications. Detection was done using Vector Stain Kit
(Vector Laboratories, Burlingame, USA) and counter-
stained with methyl green (Vector Laboratories, Burlin-
game USA). Proliferating cells and total cells were counted
in 5 different areas within 3 independent experiments
Table 1 Factor concentrations used in the experiments
AC 100 1000 μg/ml
p-15 1000 μg/ml
TP508 500 μg/ml
PDGF - BB 10 μg/ml
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using an Olympus BX51 microscope and Image Pro Plus
analysis software (Chromaphor Analysen Technik, Duis-
burg, Germany).
Calcification
The degree of mineralization was determined for osteo-
blast-like cell cultures grown on chamber slides using van
Kossa stain. Cells layers were fixed with methanol and
incubated in 3% aqueous silver nitrate (30 min). Samples
were then washed with deionized water and excess silver
was removed using 5% aqueous sodium thiosulphate for
approximately 5 min. After rinsing in distilled water, the
slices were analyzed histomorphologically using the same
microscope and software described above. At least 5 areas
(500 μm × 500 μm) in 3 independent experiments were
analyzed by 2 independent investigators.
Total RNA extraction and cDNA synthesis
RNA was extracted from cell layers using RNeasy Mini Kit
(Qiagen, Hilden, Germany) according to the manufac-
turer’s specifications and quantified spectrometrically.
Starting from 1 μg RNA, 20-μl cDNA was synthesized
using Omniscript reverse transcriptase and oligo-dT pri-
mer in presence of dNTP (Qiagen, Hilden, Germany).
Quantitative RT-PCR
Quantitative reverse transcriptase polymerase chain reac-
tions (RT-PCR) were performed and monitored using an
ABI Prism 7700 Sequence Detection System (Applied Bio-
systems, Rotkreuz, Switzerland). The PCR 2× master mix
was based on AmpliTAQ Gold DNA-Polymerase (Applied
Biosystems, Rotkreuz, Switzerland). Genes of interest were
analyzed in cDNA samples (5 μl for a total volume of
25 μl/reaction) using the standard curve method (Perkin
Elmer User Bulletin N. 2). Probes were labeled with 6-car-
boxy fluorescein (FAM) and TAMRA Cycle temperatures
and times were as previously described [23]. Primers and
probes for human alkaline phosphatase, collagen I, osteo-
calcin, and 18 s rRNA were previously described and pur-
chased from TIB Biomol, Berlin, Germany [24].
Statistical Analysis
All values are presented as mean ± standard errors (SE).
Statistics were assessed within each of the 3 independent
experiments using Mann-Whitney U-test with p < 0.05
considered to be significant.
Results
Proliferation
For the Ki-67 -indexed proliferation, combinations and
single factors induced a constant cell proliferation in
comparison to the control. Proliferation was significant
for all peptides with PDGF (p < 0.05) during the whole
time course (Figures 1, 2 and 3).
Figure 1 Proliferation indexed by Ki-67 staining for AC-100
and its combination with PDGF. Proliferation in the treated
cultures was significantly higher than the control at day 5 and 10
(*p < 0.05).
Figure 2 Proliferation indexed by Ki-67 staining for p-15 and
its combination with PDGF. Proliferation in the treated cultures
was significantly higher than the control at day 5 (*p < 0.05).
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Figures 4 and 5 show the absolute cell counts calcu-
lated from the mean values obtained from 3 indepen-
dent cultures treated with peptides and PDGF.
In comparison to control, the addition of either PDGF
or peptides or their combinations resulted in a significant
increase of proliferating cells (p < 0.05), especially in the
first 5 days. A significant increase (p < 0.05) was reached
at day 10 using PDGF/TP508, PDGF/AC-100 combina-
tions. No significant increase (p > 0.05) was observed
when proliferation was compared to cultures induced by
either of the single factors.
Calcification
Although the degree of calcification differed between the
single series, an increase of calcification relative to controls
was observed in cultures treated with the 3 PDGF combi-
nations. We found that the onset of calcification in osteo-
blasts occurred earlier and was more distinct compared to
the control. This increase in calcification was significantly
higher (p < 0.05) relative to the control for PDGF/p-15
and PDGF/AC-100 at days 5 and 10 (Figures 6, 7 and 8).
Gene expression experiments
Alkaline phosphatase
Alkaline phosphatase as a marker of bone formation was
expressed in osteoblast-like cells during long-term culti-
vation, typically showing a maximum of expression at
day 5. In our experiments, the expression was unaffected
or diminished (not significant at p > 0.05) by addition of
AC-100, TP508 and p-15 as well as their combinations
with PDGF.
Collagen I
With the exception of PDGF treatment, no increase in
collagen I expression was observed. A trend of reduced
collagen I expression was found, especially with PDGF/
Figure 3 Proliferation indexed by Ki-67 staining for TP508 and
its combination with PDGF. Proliferation in the treated cultures
was significantly higher than the control at day 5 (*p < 0.05).
Figure 4 Absolute cell counts in experiments with single
factors. (HPF = high power field) (*p < 0,001).
Figure 5 Absolute cell counts in experiments with combined
factors; (HPF = high power field) (*p < 0,001).
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AC-100 and PDGF/p-15 combinations but this did not
reach statistical significance (p > 0.05).
Osteocalcin
Long-term culture of osteoblasts resulted in a time-
dependent increase of osteocalcin gene expression,
reaching a maximum 10 days after inoculation. In the
presence of p-15 and AC-100 as well as PDGF, a 2-fold
increase of osteocalcin gene expression was observed in
at least in 2 of the 3 independent experiments at 2 and
10 days after inoculation. The combined use of PDGF
with either of the matrix-derived peptides had similar
effects on the osteocalcin expression but a 2-fold
increase in osteocalcin gene expression was observed
only in minor experiments. Over all, there were no sig-
nificant differences between the different cell culture
treatments (p > 0.05).
Discussion
This study investigated the effects of stimulation with
PDGF-BB combined with synthetic peptides on osteo-
blast-like cells, with respect to cell proliferation, calcifi-
cation and gene expression. In particular, the
cooperative action of PDGF with synthetic matrix-
derived peptides was explored.
In our experiments, stimulation with peptides exhib-
ited in a significant proliferative effect on the osteoblast-
like cells, especially within the early phase of cultivation.
Figure 6 Calcification indexed by van Kossa staining for AC-
100, PDGF, and PDGF/AC-100 combination. Increase in
calcification was significantly higher in PDGF/AC-100 than control at
days 5 and 10 (*p < 0.05).
Figure 7 Calcification indexed by van Kossa staining for p-15,
PDGF, and PDGF/p-15 combination. Increase in calcification was
significantly higher in PDGF/p-15 than control at days 5 and 10 (*p
< 0.05).
Figure 8 Calcification indexed by van Kossa staining for TP508,
PDGF, and PDGF/TP508 combination. Increase in calcification was
not significantly higher in PDGF/TP508 than control at days 5 and
10 (*p < 0.05).
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The combination of peptides with PDGF resulted in the
same proliferative effect, but showed no significant dif-
ferences when compared to the single substances. The
thrombin fragment TP508 enhances proliferation and
differentiation and induces chemotaxis in human osteo-
blasts [25]. AC-100 a synthetic fragment of MEPE, and
p-15, the 15 amino acid residue related to the biological
active domain or collagen, are known to stimulate pro-
liferation and differentiation of early uncommitted
osteoblast precursors [26] and dental pulp stem cells
[27]. In literature, AC-100 and TP508 have more prolif-
erative and differentiating effects whereas p-15 is more
of a proliferative factor. Our experiments confirm these
studies.
Focusing on the differentiation of the osteoblast-like
cells, we found that the onset of calcification in osteo-
blasts under combined stimulation occurred earlier and
was significantly higher compared to the corresponding
control or PDGF stimulation alone. This calcification was
accompanied with an alteration in the gene expression of
the matrix components collagen I and osteocalcin in
osteoblasts. This may be indicative of a cooperative effect
between extracellular matrix (ECM) molecules, peptides
and PDGF-BB. It is consistent with observations in other
cell types where such effects between integrin, adhesions,
growth factors and PDGF have been elucidated [28,29].
Bartold et al. [30] reported that PDGF-BB stimulated the
synthesis of proteoglycans. Proteoglycan synthesis pre-
cedes collagen synthesis and cell surface proteoglycans
can bind a number of growth or cell motility factors
[30-32]. The newly formed ECM is an important regula-
tor of cell migration und differentiation. Therefore, the
effect of PDGF-BB on collagen synthesis may play an
important role in the calcification together with the effect
on proteoglycan synthesis. It is reported that the extracel-
lular signal-regulated kinase (ERK) is activated and
modulated by PDGF [31,33].
Cell migration studies indicated that PDGF stimulates
migration, but has no effect on proliferation. These results
were not confirmed by our findings. Wildemann et al. [34]
also observed no cell migration under PGDF stimulation
released from a drug delivery system but reported an
increased proliferation of osteoblasts.
Chaudhary et al. [35] reported that PDGF-BB-treated
cells showed very low alkaline phosphatase activity, indi-
cating that PDGF-BB is a potent proliferative factor for
osteoblasts but not a factor for differentiation and miner-
alization [36]. These findings were confirmed by Kono et
al. who suggested that the ERK pathway activated by
PDGF is a negative regulator of matrix mineralization
[37].
Our data gave evidence that the interaction between
PDGF and the ECM can be stimulated by biologically
active peptides.
As PDGF has been identified as a paracrine factor result-
ing from the fracture hematoma [38], we speculate that
combined use of one of the matrix derived peptides with
PDGF-BB is a useful tool to enhance fracture healing or
promote healing of osteoarthritis defects.
One limitation of the study maybe the possible inter-
actions between serum in the culture medium and the
PDGF-peptide combinations that could modify the over
all effects. This should be addressed in future studies.
Conclusions
In conclusion, our findings support the hypothesis that the
combined use of PDGF-BB with synthetic peptides could
result in an increase in proliferation and calcification of
osteoblast-like cell. We suggest based on our findings that
the combined stimulation of osteoblasts with synthetic
peptides and PDGF could accelerate bone healing through
cooperative effects. These effects have a potential clinical
application in coating osteosynthesis materials to acceler-
ate bone healing. However, further studies in vitro and in
vivo are warranted.
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